MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at…
MaaT PharmaDecember 8, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results…
MaaT PharmaSeptember 17, 2025
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…
MaaT PharmaMay 14, 2025
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…
MaaT PharmaOctober 15, 2024
MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd…
MaaT PharmaApril 22, 2024
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in…
MaaT PharmaApril 15, 2024
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be…
MaaT PharmaMarch 12, 2024
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial…
MaaT PharmaMarch 5, 2024
